<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Synthetic, low-molecular weight thrombin inhibitors may substitute for antithrombin III in inactivating thrombin in vitro and in vivo </plain></SENT>
<SENT sid="1" pm="."><plain>They are superior to <z:chebi fb="5" ids="28304">heparin</z:chebi> as antithrombotic agents in <z:e sem="disease" ids="C0272375" disease_type="Disease or Syndrome" abbrv="">antithrombin deficiency</z:e> or consumption </plain></SENT>
<SENT sid="2" pm="."><plain>Studies in experimental animals show the effectiveness of synthetic thrombin inhibitors in immunologic antithrombin <z:mpath ids='MPATH_63'>depletion</z:mpath>, thrombin-induced consumption and <z:chebi fb="0" ids="27385">CCl4</z:chebi>-induced <z:hpo ids='HP_0001399'>liver failure</z:hpo> </plain></SENT>
</text></document>